HCC

HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has built a robust internal R&D engine that has produced a deep pipeline of differentiated small molecule inhibitors targeting various tyrosine kinases and other oncogenic drivers. Its lead products include fruquintinib (Elunate), approved for colorectal cancer, and surufatinib (Sulanda), approved for neuroendocrine tumors. HUTCHMED operates globally with significant R&D and manufacturing footprints in China and strategic partnerships with major global pharmaceutical companies to expand the reach of its oncology portfolio.